Maja Tomičić
- Cancer Research top 5%
- Oncology top 5%
- Cancer-related Molecular Pathways 15
- Molecular Biology top 5%
- DNA Repair Mechanisms 27
- Cell death mechanisms and regulation 10
- Cancer therapeutics and mechanisms 8
- Genetics top 5%
- Glioma Diagnosis and Treatment 8
- Blood disorders and treatments 7
- Toxicology top 5%
-
- Blood groups and transfusion 9
- Platelet Disorders and Treatments 8
- Co-authors
- Bernd KainaMarkus ChristmannWynand P. RoosBeate KöberleDorthe AaslandR ThustThomas EfferthMirza Bojić
- Partner nations
- GermanyCroatiaUnited States
In The Last Decade
Maja Tomičić
80 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 125
- Cancer Research 614
- Oncology 783
- Molecular Biology 1.9k
- Genetics 268
- Toxicology 44
Countries citing papers authored by Maja Tomičić
This map shows the geographic impact of Maja Tomičić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maja Tomičić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maja Tomičić more than expected).
Fields of papers citing papers by Maja Tomičić
This network shows the impact of papers produced by Maja Tomičić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maja Tomičić. The network helps show where Maja Tomičić may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Maja Tomičić, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 11 | |
| 5 | 2022 | 24 | |
| 6 | 2021 | 19 | |
| 7 | 2021 | 25 | |
| 8 | 2020 | 30 | |
| 9 | 2019 | 51 | |
| 10 | 2018 | 147 | |
| 11 | 2017 | 40 | |
| 12 | [Indications and contraindications for platelet transfusions in patients with thrombocytopenia]. | 2015 | 1 |
| 13 | 2014 | 52 | |
| 14 | INDIKACIJE I KONTRAINDIKACIJE ZA PRIMJENU TROMBOCITNIH TRANSFUZIJA U BOLESNIKA S TROMBOCITOPENIJOM | 2014 | 1 |
| 15 | 2010 | 305 | |
| 16 | 2010 | 54 | |
| 17 | 5, 10-Methylenetetrahydrofolate reductase (MTHFR) 677 C --> T genetic polymorphism in 228 Croatian volunteers. | 2004 | 10 |
| 18 | 2001 | 81 | |
| 19 | 2000 | 46 | |
| 20 | [Nationally produced 153SmEDTMP in the palliative treatment of metastatic bone cancer pain]. | 1996 | 2 |
About Maja Tomičić
Maja Tomičić is a scholar working on Hematology, Biochemistry and Genetics, having authored 83 papers that have together received 3.0k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (27 papers), Cancer-related Molecular Pathways (15 papers), Cell death mechanisms and regulation (10 papers), Blood groups and transfusion (9 papers), Glioma Diagnosis and Treatment (8 papers), Cancer therapeutics and mechanisms (8 papers), Platelet Disorders and Treatments (8 papers) and Blood disorders and treatments (7 papers). The work is most often cited by research in Cancer Research (614 citations), Oncology (783 citations) and Molecular Biology (1.9k citations). Maja Tomičić has collaborated with scholars based in Germany, Croatia and United States. Frequent co-authors include Bernd Kaina, Markus Christmann, Wynand P. Roos, Beate Köberle, Dorthe Aasland, R Thust, Thomas Efferth, Mirza Bojić, Rolf Rauh and Sabine Grösch.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.